Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: The present study was designed to investigate the equivalence of two target activated clotting time (ACT) values with regard to packed red blood cell (PRBC) transfusion in patients undergoing cardiac surgery with cardiopulmonary bypass (CPB). Secondary endpoints include postoperative blood loss, transfusion of other blood products, and postoperative laboratory parameters, including renal function, intensive care unit length of stay, postoperative thrombotic events, and other adverse events.
Design: Multicenter, randomized, single-blind, controlled equivalence trial. Patients were randomized to a lower target ACT of ≥400 seconds or a higher target ACT of ≥480 seconds.
Setting: Three tertiary and one university medical center in the Netherlands.
Participants: 1,021 patients ≥18 years of age scheduled for first-time elective cardiac surgery with CPB between November 2019 and December 2023.
Measurements And Main Results: PRBC transfusion was equivalent in both ACT groups (19.1% v 17.2% risk difference -0.029; 0.066). In the low ACT group, blood loss at 6 and 24 hours postoperative was significantly lower (median [interquartile range], 260 [245] v 300 [250] mL, p = 0.003 and 480 [363] v 550 [410] mL, p = 0.007) and the hemoglobin level at 6 hours and 1 day after surgery significantly higher (mean [95% confidence interval], 11.8 [11.6-11.9] v 11.6 [11.3-11.8] g/dL, p = 0.017 and 11.4 [11.1-11.6] v 11.1 [11.0-11.4] g/dL, p = 0.045) compared with the high ACT group, but lacking clinical relevance. The frequency of thromboembolic events was similar in both groups.
Conclusions: This study showed that a target ACT of ≥400 seconds is equivalent to a target ACT of ≥480 seconds in terms of intraoperative and postoperative PRBC transfusion rates in the modern cardiac surgery setting. This target range is considered comparable regarding the outcomes of patients undergoing cardiac surgery with CPB.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/j.jvca.2025.07.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reducing motion artifacts in craniocervical background subtraction angiography with deformable registration and unsupervised deep learning.
Radiol Adv
September 2024
Department of Radiology, Northwestern University and Northwestern Medicine, Chicago, IL, 60611, United States.
Background: In clinical practice, digital subtraction angiography (DSA) often suffers from misregistration artifact resulting from voluntary, respiratory, and cardiac motion during acquisition. Most prior efforts to register the background DSA mask to subsequent postcontrast images rely on key point registration using iterative optimization, which has limited real-time application.
Purpose: Leveraging state-of-the-art, unsupervised deep learning, we aim to develop a fast, deformable registration model to substantially reduce DSA misregistration in craniocervical angiography without compromising spatial resolution or introducing new artifacts.
Integrative profiling of lung cancer biomarkers EGFR, ALK, KRAS, and PD-1 with emphasis on nanomaterials-assisted immunomodulation and targeted therapy.
Front Immunol
September 2025
Department of Thoracic Surgery, Shenzhen People's Hospital (The First Affiliated Hospital, Southern University of Science and Technology; The Second Clinical Medical College, Jinan University), Shenzhen, Guangdong, China.
Background: Lung cancer remains the leading cause of cancer-related mortality globally, primarily due to late-stage diagnosis, molecular heterogeneity, and therapy resistance. Key biomarkers such as EGFR, ALK, KRAS, and PD-1 have revolutionized precision oncology; however, comprehensive structural and clinical validation of these targets is crucial to enhance therapeutic efficacy.
Methods: Protein sequences for EGFR, ALK, KRAS, and PD-1 were retrieved from UniProt and modeled using SWISS-MODEL to generate high-confidence 3D structures.
Results of a Retrospective FDA Investigational Device Exemption Study for Anterior Vertebral Body Tethering in Adolescent Idiopathic Scoliosis with 3-Year to 10-Year Follow-Up.
JB JS Open Access
September 2025
Shriners Children's Philadelphia, Philadelphia, Pennsylvania.
Background: Vertebral body tethering (VBT) offers an alternative treatment for patients with idiopathic scoliosis. We present our finalized Food and Drug Administration Investigational Device Exemption (IDE) study results on VBT.
Methods: We retrospectively reviewed patients with Lenke Type IA/B curves who underwent VBT between 2011 and 2015.
Reciprocated tachycardias in cardiac laminopathy: a clinical case report.
Eur Heart J Case Rep
September 2025
Feinberg School of Medicine, Northwestern University, 303E Chicago Ave, Ward 1-003, Chicago, IL 60611, USA.
Background: Cardiac laminopathies, associated with mutations in the LMNA gene, are a rare inherited disorder characterized by a broad range of clinical manifestations. There are currently no data on the association between supraventricular re-entrant tachycardias and LMNA-related cardiomyopathy.
Case Summary: A 26-year-old male presented with either wide-QRS tachycardia with a left bundle branch block (LBBB) pattern or narrow QRS tachycardia, as well as a history of palpitations since age 15.
Breast cancer surgery under mechanical circulatory support in a patient with cancer therapy-related cardiac dysfunction: a case report.
Eur Heart J Case Rep
September 2025
Cardiovascular Department, Tokushima University Hospital, 7708503 Kuramoto-cho, Tokushima 2-50-1, Japan.
Background: The incidence of cancer therapy-related cardiac dysfunction is increasing with the growing number of breast cancer patients. In particular, patients with active cancer combined with severe irreversible cardiac dysfunction present significant challenges in treatment decision-making.
Case Summary: A 40-year-old woman with Stage II HER-2-positive breast cancer received anthracycline followed by HER2-targeted agents.